Ghazal Alagh after the IPO: rebuilding Mamaearth's brand math under public-market scrutiny

Ghazal Alagh's role at Honasa Consumer has evolved substantially in the twelve to eighteen months since the company's October 2023 listing, shifting from the high-visibility brand ambassador function that defined the company's Shark Tank-era growth story toward a more operationally focused leadership posture that reflects the demands of managing a publicly listed consumer company through quarterly earnings cycles and analyst scrutiny. The co-founder has been publicly visible on product strategy and the portfolio-brand expansion, particularly around The Derma Co. and the newer Aqualogica brand, while the distribution and financial management functions have been strengthened with professional hires. The post-IPO operating environment has been harder than the listing circumstances suggested. Honasa's first year as a public company included several quarters where results came in below analyst estimates, driven by a combination of a deliberate pullback in performance marketing spend - which management judged to be inflating topline growth without building sustainable brand equity - and a competitive response from established FMCG players who have accelerated their own natural and toxin-free formulation ranges in response to Mamaearth's success. The stock traded below its IPO price for extended periods before recovering, creating a period of reputational pressure that few Indian D2C founders had previously experienced. The strategic response has centred on offline distribution depth, portfolio diversification and gross-margin defence. The company's push into pharmacy retail - partnering with chains like Apollo Pharmacy and MedPlus to create dedicated beauty and personal-care sections - represents a channel that the direct-to-consumer model had previously underutilised. Pharmacy retail customers tend to be more purchase-intent-driven and less price-sensitive than mass marketplace shoppers, which should, over time, improve the revenue quality even if it requires investment in trade marketing. The Derma Co.'s performance has been the most encouraging signal from the portfolio expansion. The dermatology-inspired skincare brand has been growing faster than the parent Mamaearth brand, and its higher price point and active-ingredient formulation positioning has attracted a distinct consumer segment - urban women in their mid-to-late twenties who have been influenced by Korean skincare routines and are willing to pay for clinical-sounding formulations. This brand's trajectory has partially offset the narrative about Mamaearth's own market maturation. What to watch: whether the gross-margin recovery from the reduced-advertising strategy materialises in the Q3 and Q4 results, how The Derma Co.'s revenue trajectory affects the overall portfolio mix over the next two years, and whether Honasa Consumer announces any acquisitions that add a third growth brand to supplement the existing portfolio.

Original source: Moneycontrol